Results 91 to 100 of about 36,256 (261)

Figure S3 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

, 2023
Xuyang Song, Robin Kate Kelley, Anis A. Khan, Nathan Standifer, Diansong Zhou, KyoungSoo Lim, Rajesh Krishna, Lu Liu, Kun Wang, Patricia McCoon, Alejandra Negro, Philip He, Megan Gibbs, John F. Kurland, Ghassan K. Abou‐Alfa   +14 more
openalex   +2 more sources

PD-L1 inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: a French nationwide cohort studyResearch in context

The Lancet Regional Health. Europe
Summary: Background: Immunotherapy with atezolizumab and durvalumab has significantly advanced the treatment of extended-stage small cell lung cancer (esSCLC).
Hugo Jourdain, Nicolas Albin, Adrien Monard, David Desplas, Mahmoud Zureik, Nadia Haddy   +5 more
doaj   +1 more source

Bullous dermatoses secondary to anti-PD-L1 agents: a case report and review of the literature [PDF]

, 2019
Immune checkpoint inhibitors are used to treat numerous malignancies but may be associated with severe adverse events. Bullous dermatoses, chiefly bullous pemphigoid (BP), are potentially progressive adverse events that cause blistering skin lesions and ...
Choi, Jennifer N, Kosche, Cory, Owen, Joshua L, Sadowsky, Lauren M   +3 more
core  

Durvalumab (Imfinzi)

, 2023
CADTH
openalex   +2 more sources

79MO PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy [PDF]

, 2021
Fiona McDonald, F. Mornex, Marina Chiara Garassino, Andrea Riccardo Filippi, Daniel C. Christoph, Vilde Drageset Haakensen, Abed Agbarya, Michel M. van den Heuvel, Piet Vercauter, C. Chouaïd, Éric Pichon, Shankar Siva, L. Steinbusch, Idit Peretz, Benjamin Solomon, Lore Decoster, W. Sawyer, A. Allen, Muriel Licour, Nicolas Girard   +19 more
openalex   +1 more source

Clinical Outcomes of Reduced‐Dose Cabozantinib as Third‐ or Later‐Line Therapy After Immune Checkpoint Inhibitors in Advanced Hepatocellular Carcinoma: A Real‐World Study

Hepatology Research, EarlyView.
In this real‐world post‐ICI setting, cabozantinib demonstrated meaningful clinical activity even at reduced doses, with disease control achieved in nearly half of patients. Importantly, preserved liver function (Child–Pugh class A) was the only determinant of both disease control and overall survival.
Teiji Kuzuya, Hisanori Muto, Yoshihiko Tachi, Mizuki Ariga, Sayaka Morisaki, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Ryoji Miyahara, Yoshiki Hirooka   +13 more
wiley   +1 more source

Irradiation to Improve the Response to Immunotherapeutic Agents in Glioblastomas. [PDF]

, 2019
PurposeGlioblastoma (GBM) remains an incurable disease despite extensive treatment with surgical resection, irradiation, and temozolomide. In line with many other forms of aggressive cancers, GBM is currently under consideration as a target for ...
Kaprealian, Tania, Lee, Mi-Heon, McBride, William H, Nesseler, Jean Philippe, Nickers, Philippe, Niclou, Simone P, Schaue, Dorthe   +6 more
core  

Anti-CTLA-4 therapy for malignant mesothelioma [PDF]

, 2017
Immunotherapy is an emerging therapeutic strategy with a promising clinical outcome in some solid tumors, particularly metastatic melanoma. One approach to immunotherapy is immune checkpoint inhibitors, such as blockage of CTLA-4 and PD-1/PD-L1.
Bakker, EY, Guazzelli, A, Krstic-Demonacos, M, Lisanti, MP, Mutti, L, Sotgia, F   +5 more
core   +2 more sources

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

Supplementary Methods S1 from Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial

, 2023
Shuchi Gulati, McKenzie Crist, Muhammed Kashif Riaz, Vinita Takiar, Maria Lehn, Ilaina Monroe, Sarah Palackdharry, Nicky Kurtzweil, Roman Jandarov, Nusrat Harun, Trisha M. Wise‐Draper   +10 more
openalex   +2 more sources